MAPT and tauopathy: The current findings demonstrate that administration of GPD for 21 continuous days shows marked effects on tau pathology and tauopathy and distinct reduction in phosphorylated tau in both cortex and hippocampus mainly by affecting phosphorylating kinases and dephosphorylating phosphatases which regulate tau aggregation.